Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de John Tsai
Age : 53
Public asset : 6,594,235 USD
Country of residence : Unknown
Linked companies : Novartis AG

Biography of John Tsai 
Presently, John Tsai is Chief Medical Officer at Novartis AG. In his past career Dr. Tsai was Chief Medical Officer & SVP-Global Medical at Amgen, Inc. and Head-Clinical Development at Bristol Myers Squibb Co. He received a doctorate from the University of Louisville School of Medicine and an undergraduate degree from Washington University in St. Louis.


Current positions of John Tsai 
Holdings of John Tsai 
John Tsai : Personal Network 
Most Read News 
11/23ELON MUSK : Tesla's Musk exercises more options, sells shares worth $1.05 billion
RE
11/30JACK DORSEY : Jack Dorsey chases crypto, fintech dream post Twitter
RE
11/24JAMIE DIMON : Jamie Dimon jokes that JPMorgan will outlast China's Communist Party
RE
12/01JACK DORSEY : Dorsey-led Square rebrands to Block in nod to blockchain
RE
11/26ELON MUSK : Tesla decides against state aid for German battery plant as Musk opposes subsidies
RE
11/23ERIK NORDSTROM : Nordstrom warns of supply shortages as holiday season approaches, shares plunge
RE
11/22MUKESH AMBANI : India's salesmen face ruin as tycoon Ambani targets mom-and-pop stores
RE
11/29ANIL AMBANI : India central bank to start bankruptcy procedure against Reliance Capital; co to comply
RE
11/29JACK DORSEY : Twitter CEO Jack Dorsey hands reins to technology chief Agrawal
RE
11/24HERBERT DIESS : Factbox-Possible successors to Volkswagen CEO Diess
RE
More news


© 2021 People and Ownership :   
John Tsai : Connections 


Latest news about John Tsai 
10/25NOVARTIS : lung cancer drug fails another Phase III trial
RE
10/25PRESS RELEASE : Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
DJ
06/11PRESS RELEASE : Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
DJ
06/07NOVARTIS' : Iptacopan Trial in Rare Kidney Disease Meets Primary Endpoint
MT
06/06PRESS RELEASE : Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
DJ
06/03PRESS RELEASE : Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
DJ
06/03NOVARTIS' : nuclear therapy helps men with prostate cancer live longer - data
RE
More news